Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 13.2% – Here’s Why

by · The Cerbat Gem

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares rose 13.2% during trading on Monday . The company traded as high as $8.06 and last traded at $8.04. Approximately 4,246,413 shares changed hands during trading, a decline of 25% from the average daily volume of 5,661,439 shares. The stock had previously closed at $7.10.

Analysts Set New Price Targets

A number of research analysts recently issued reports on RXRX shares. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, November 7th. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group reduced their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $9.40.

Get Our Latest Stock Report on RXRX

Recursion Pharmaceuticals Trading Down 3.4 %

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a fifty day moving average price of $6.61 and a 200-day moving average price of $7.62.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the business posted ($0.43) EPS. The firm’s revenue was up 147.6% on a year-over-year basis. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the sale, the chief operating officer now directly owns 521,138 shares in the company, valued at approximately $3,939,803.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total value of $45,360.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares in the company, valued at $3,939,803.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 156,682 shares of company stock worth $1,012,618 over the last three months. 15.75% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC increased its holdings in Recursion Pharmaceuticals by 16.4% during the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after acquiring an additional 4,626,268 shares in the last quarter. Baillie Gifford & Co. increased its stake in shares of Recursion Pharmaceuticals by 10.5% during the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after purchasing an additional 2,522,132 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Recursion Pharmaceuticals by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company’s stock worth $159,667,000 after purchasing an additional 349,554 shares during the last quarter. Kinnevik AB publ lifted its stake in Recursion Pharmaceuticals by 14.4% in the 2nd quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock valued at $89,293,000 after buying an additional 1,500,000 shares in the last quarter. Finally, FMR LLC increased its position in Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after buying an additional 170,810 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Featured Stories